Sequence-specific DNA binding by p53: identification of target sites and lack of binding to p53 - MDM2 complexes - PubMed (original) (raw)

Sequence-specific DNA binding by p53: identification of target sites and lack of binding to p53 - MDM2 complexes

A Zauberman et al. EMBO J. 1993 Jul.

Abstract

An immune selection procedure was employed in order to isolate p53 binding sites from mouse genomic DNA. Two DNA clones capable of tight specific interaction with wild type p53 were subjected to further characterization. In both cases, the p53 binding regions displayed a high degree of sequence homology with the consensus binding site defined for human genomic DNA. One of the clones was found to be derived from the LTR of a retrovirus-like element (a member of the GLN family). The region encompassing the GLN LTR p53 binding site could confer p53 responsiveness upon a heterologous promoter. Furthermore, the expression of the endogenous, chromosomally integrated GLN elements was significantly induced upon activation of wild type p53 in cells harboring a temperature sensitive p53 mutant. Finally, it was demonstrated that p53 - MDM2 complexes fail to bind tightly to such a p53 binding site. This may contribute to the inhibition by MDM2 of p53-mediated transcriptional activation.

PubMed Disclaimer

Similar articles

• Targets for transcriptional activation by wild-type p53: endogenous retroviral LTR, immunoglobulin-like promoter, and an internal promoter of the mdm2 gene.
  Barak Y, Lupo A, Zauberman A, Juven T, Aloni-Grinstein R, Gottlieb E, Rotter V, Oren M. Barak Y, et al. Cold Spring Harb Symp Quant Biol. 1994;59:225-35. doi: 10.1101/sqb.1994.059.01.027. Cold Spring Harb Symp Quant Biol. 1994. PMID: 7587074 No abstract available.
• p53 binds to a constitutively nucleosome free region of the mdm2 gene.
  Xiao G, White D, Bargonetti J. Xiao G, et al. Oncogene. 1998 Mar 5;16(9):1171-81. doi: 10.1038/sj.onc.1201631. Oncogene. 1998. PMID: 9528859
• The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation.
  Momand J, Zambetti GP, Olson DC, George D, Levine AJ. Momand J, et al. Cell. 1992 Jun 26;69(7):1237-45. doi: 10.1016/0092-8674(92)90644-r. Cell. 1992. PMID: 1535557
• The MDM2-p53 interaction.
  Moll UM, Petrenko O. Moll UM, et al. Mol Cancer Res. 2003 Dec;1(14):1001-8. Mol Cancer Res. 2003. PMID: 14707283 Review.
• Inhibition of the p53-MDM2 interaction: targeting a protein-protein interface.
  Chène P. Chène P. Mol Cancer Res. 2004 Jan;2(1):20-8. Mol Cancer Res. 2004. PMID: 14757842 Review.

Cited by

• Therapeutic considerations for Mdm2: not just a one trick pony.
  Lehman JA, Eitel JA, Batuello CN, Mayo LD. Lehman JA, et al. Expert Opin Drug Discov. 2008 Nov;3(11):1309-1321. doi: 10.1517/17460441.3.11.1309. Expert Opin Drug Discov. 2008. PMID: 19738896 Free PMC article.
• Wild-type alternatively spliced p53: binding to DNA and interaction with the major p53 protein in vitro and in cells.
  Wu Y, Liu Y, Lee L, Miner Z, Kulesz-Martin M. Wu Y, et al. EMBO J. 1994 Oct 17;13(20):4823-30. doi: 10.1002/j.1460-2075.1994.tb06808.x. EMBO J. 1994. PMID: 7957051 Free PMC article.
• A functional p53-responsive intronic promoter is contained within the human mdm2 gene.
  Zauberman A, Flusberg D, Haupt Y, Barak Y, Oren M. Zauberman A, et al. Nucleic Acids Res. 1995 Jul 25;23(14):2584-92. doi: 10.1093/nar/23.14.2584. Nucleic Acids Res. 1995. PMID: 7651818 Free PMC article.
• The c-fos proto-oncogene is a target for transactivation by the p53 tumor suppressor.
  Elkeles A, Juven-Gershon T, Israeli D, Wilder S, Zalcenstein A, Oren M. Elkeles A, et al. Mol Cell Biol. 1999 Apr;19(4):2594-600. doi: 10.1128/MCB.19.4.2594. Mol Cell Biol. 1999. PMID: 10082525 Free PMC article.
• Adenovirus E1B 55K represses p53 activation in vitro.
  Martin ME, Berk AJ. Martin ME, et al. J Virol. 1998 Apr;72(4):3146-54. doi: 10.1128/JVI.72.4.3146-3154.1998. J Virol. 1998. PMID: 9525640 Free PMC article.

References

1. 1. J Exp Med. 1981 Feb 1;153(2):269-79 - PubMed
2. 1. FASEB J. 1992 Oct;6(13):3169-76 - PubMed
3. 1. Mol Cell Biol. 1984 Sep;4(9):1689-94 - PubMed
4. 1. Cell. 1992 Nov 27;71(5):875-86 - PubMed
5. 1. Mol Cell Biol. 1992 Dec;12(12):5581-92 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Europe PubMed Central
  • Nature Publishing Group
  • PubMed Central
  • Wiley

• Other Literature Sources

  • The Lens - Patent Citations Database

• Research Materials

  • NCI CPTC Antibody Characterization Program

• Miscellaneous

  • NCI CPTAC Assay Portal